Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375451 | 1.00 | OPRM1 (0.41) | OPRM1SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL27625956 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A9SLC6A5SLC18A3 | |
| SCHEMBL27625955 | 0.81 | OPRM1 (0.42) | OPRM1SLC6A9SLC6A5SLC18A3 | |
| SCHEMBL27625962 | 0.79 | SLC6A9 (0.44) | SLC6A9SLC6A5MEN1KMT2ASLC18A3 | |
| SCHEMBL27625963 | 0.79 | SLC6A9 (0.44) | SLC6A9SLC6A5MEN1KMT2ASLC18A3 | |
| SCHEMBL6150894 | 0.78 | MEN1 (0.52) | OPRM1SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL28758537 | 0.77 | SLC6A2 (0.46) | OPRM1SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL28758536 | 0.77 | SLC6A2 (0.46) | OPRM1SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL27626122 | 0.75 | CHRM2 (0.48) | OPRM1SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL27626119 | 0.75 | CHRM2 (0.48) | OPRM1SLC6A9SLC6A5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176316-B2 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594840-B1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167166-A1 | Amino-piperidine derivatives | OPRL1, GRIA1, GRIN1 | OPRM1 31/4885SLC6A9 414/4885SLC6A5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.